Vertex Pharmaceuticals Inc. buy stratec
Start price
14.01.18
/
50%
€142.77
Target price
11.01.19
€170.18
Performance (%)
18.71%
End price
11.01.19
€169.48
Summary
This prediction ended on 11.01.19 with a price of €169.48. The prediction had a final performance of 18.71%. stratec has a follow-up prediction for Vertex Pharmaceuticals Inc. where he still thinks Vertex Pharmaceuticals Inc. is a Buy. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Vertex Pharmaceuticals Inc. | -1.509% | -1.509% | -13.165% | 29.153% |
| iShares Core DAX® | 0.734% | -0.964% | 17.910% | 65.510% |
| iShares Nasdaq 100 | -2.686% | -2.409% | 4.267% | 95.368% |
| iShares Nikkei 225® | -2.261% | -4.038% | 10.420% | 42.232% |
| iShares S&P 500 | -1.346% | -1.510% | 1.615% | 59.132% |
Comments by stratec for this prediction
In the thread Vertex Pharmaceuticals Inc. diskutieren
Vertex wins expanded approval for its cystic fibrosis combo
Looking forward: VRTX moves the needle here with this approval. Now, it would appear as though the European approval matches that in America, and this can be a good tool for young patients with this form of cystic fibrosis. The $250,000+ price tag on Orkambi means that even with only reaching a third of the patients, the company stands to gain hundreds of millions in revenue a year from this.
stratec stimmt am 14.01.2018 der Outperform-Einschätzung der institutionellen Analysten aber mit dem Kursziel 188,67$ zu.
(Vom Mitglied beendet)
Current prediction by stratec for Vertex Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€414.00
09.04.25
09.04.25
€480.00
09.04.26
09.04.26
-6.96%
12.12.25
12.12.25
